These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 33300544)

  • 1. O-GlcNAcylation regulates dopamine neuron function, survival and degeneration in Parkinson disease.
    Lee BE; Kim HY; Kim HJ; Jeong H; Kim BG; Lee HE; Lee J; Kim HB; Lee SE; Yang YR; Yi EC; Hanover JA; Myung K; Suh PG; Kwon T; Kim JI
    Brain; 2020 Dec; 143(12):3699-3716. PubMed ID: 33300544
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Age-dependent nigral dopaminergic neurodegeneration and α-synuclein accumulation in RGS6-deficient mice.
    Luo Z; Ahlers-Dannen KE; Spicer MM; Yang J; Alberico S; Stevens HE; Narayanan NS; Fisher RA
    JCI Insight; 2019 May; 5(13):. PubMed ID: 31120439
    [TBL] [Abstract][Full Text] [Related]  

  • 3. α-Synuclein O-GlcNAcylation alters aggregation and toxicity, revealing certain residues as potential inhibitors of Parkinson's disease.
    Levine PM; Galesic A; Balana AT; Mahul-Mellier AL; Navarro MX; De Leon CA; Lashuel HA; Pratt MR
    Proc Natl Acad Sci U S A; 2019 Jan; 116(5):1511-1519. PubMed ID: 30651314
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progressive neurodegenerative and behavioural changes induced by AAV-mediated overexpression of α-synuclein in midbrain dopamine neurons.
    Decressac M; Mattsson B; Lundblad M; Weikop P; Björklund A
    Neurobiol Dis; 2012 Mar; 45(3):939-53. PubMed ID: 22182688
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The emerging link between O-GlcNAcylation and neurological disorders.
    Ma X; Li H; He Y; Hao J
    Cell Mol Life Sci; 2017 Oct; 74(20):3667-3686. PubMed ID: 28534084
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Small GTPase RAC1/CED-10 Is Essential in Maintaining Dopaminergic Neuron Function and Survival Against α-Synuclein-Induced Toxicity.
    Kim H; Calatayud C; Guha S; Fernández-Carasa I; Berkowitz L; Carballo-Carbajal I; Ezquerra M; Fernández-Santiago R; Kapahi P; Raya Á; Miranda-Vizuete A; Lizcano JM; Vila M; Caldwell KA; Caldwell GA; Consiglio A; Dalfo E
    Mol Neurobiol; 2018 Sep; 55(9):7533-7552. PubMed ID: 29429047
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Repulsive Guidance Molecule a (RGMa) Induces Neuropathological and Behavioral Changes That Closely Resemble Parkinson's Disease.
    Korecka JA; Moloney EB; Eggers R; Hobo B; Scheffer S; Ras-Verloop N; Pasterkamp RJ; Swaab DF; Smit AB; van Kesteren RE; Bossers K; Verhaagen J
    J Neurosci; 2017 Sep; 37(39):9361-9379. PubMed ID: 28842419
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of functional dopamine neurons from human astrocytes in vitro and mouse astrocytes in a Parkinson's disease model.
    Rivetti di Val Cervo P; Romanov RA; Spigolon G; Masini D; Martín-Montañez E; Toledo EM; La Manno G; Feyder M; Pifl C; Ng YH; Sánchez SP; Linnarsson S; Wernig M; Harkany T; Fisone G; Arenas E
    Nat Biotechnol; 2017 May; 35(5):444-452. PubMed ID: 28398344
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective expression of Parkinson's disease-related Leucine-rich repeat kinase 2 G2019S missense mutation in midbrain dopaminergic neurons impairs dopamine release and dopaminergic gene expression.
    Liu G; Sgobio C; Gu X; Sun L; Lin X; Yu J; Parisiadou L; Xie C; Sastry N; Ding J; Lohr KM; Miller GW; Mateo Y; Lovinger DM; Cai H
    Hum Mol Genet; 2015 Sep; 24(18):5299-312. PubMed ID: 26123485
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Depopulation of dense α-synuclein aggregates is associated with rescue of dopamine neuron dysfunction and death in a new Parkinson's disease model.
    Wegrzynowicz M; Bar-On D; Calo' L; Anichtchik O; Iovino M; Xia J; Ryazanov S; Leonov A; Giese A; Dalley JW; Griesinger C; Ashery U; Spillantini MG
    Acta Neuropathol; 2019 Oct; 138(4):575-595. PubMed ID: 31165254
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diminished O-GlcNAcylation in Alzheimer's disease is strongly correlated with mitochondrial anomalies.
    Pinho TS; Correia SC; Perry G; Ambrósio AF; Moreira PI
    Biochim Biophys Acta Mol Basis Dis; 2019 Aug; 1865(8):2048-2059. PubMed ID: 30412792
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system.
    Kirik D; Rosenblad C; Burger C; Lundberg C; Johansen TE; Muzyczka N; Mandel RJ; Björklund A
    J Neurosci; 2002 Apr; 22(7):2780-91. PubMed ID: 11923443
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protein kinase Cδ upregulation in microglia drives neuroinflammatory responses and dopaminergic neurodegeneration in experimental models of Parkinson's disease.
    Gordon R; Singh N; Lawana V; Ghosh A; Harischandra DS; Jin H; Hogan C; Sarkar S; Rokad D; Panicker N; Anantharam V; Kanthasamy AG; Kanthasamy A
    Neurobiol Dis; 2016 Sep; 93():96-114. PubMed ID: 27151770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conditional deletion of Ndufs4 in dopaminergic neurons promotes Parkinson's disease-like non-motor symptoms without loss of dopamine neurons.
    Choi WS; Kim HW; Tronche F; Palmiter RD; Storm DR; Xia Z
    Sci Rep; 2017 Mar; 7():44989. PubMed ID: 28327638
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acutely elevated O-GlcNAcylation suppresses hippocampal activity by modulating both intrinsic and synaptic excitability factors.
    Hwang H; Rhim H
    Sci Rep; 2019 May; 9(1):7287. PubMed ID: 31086206
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overview of mouse models of Parkinson's disease.
    Bobela W; Zheng L; Schneider BL
    Curr Protoc Mouse Biol; 2014 Sep; 4(3):121-39. PubMed ID: 25723963
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute Increases in Protein O-GlcNAcylation Dampen Epileptiform Activity in Hippocampus.
    Stewart LT; Khan AU; Wang K; Pizarro D; Pati S; Buckingham SC; Olsen ML; Chatham JC; McMahon LL
    J Neurosci; 2017 Aug; 37(34):8207-8215. PubMed ID: 28760863
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evidence for dopaminergic axonal degeneration as an early pathological process in Parkinson's disease.
    O'Keeffe GW; Sullivan AM
    Parkinsonism Relat Disord; 2018 Nov; 56():9-15. PubMed ID: 29934196
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthetic alpha-synuclein fibrils cause mitochondrial impairment and selective dopamine neurodegeneration in part via iNOS-mediated nitric oxide production.
    Tapias V; Hu X; Luk KC; Sanders LH; Lee VM; Greenamyre JT
    Cell Mol Life Sci; 2017 Aug; 74(15):2851-2874. PubMed ID: 28534083
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Ophthalmic disorders as a manifestation of Parkinson's disease].
    Chesnokova NB; Pavlenko TA; Ugrumov MV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(9):124-131. PubMed ID: 29053133
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.